XVIPF

Healthcare Medical Devices

Xvivo Perfusion AB (publ)

$21.80
-1.05 -4.60% today

Price History

Not enough data

Key Stats

Market Cap
686.69M
Avg Volume
105
P/E (TTM)
77.86
EPS
$0.28
52W High
$30.95
52W Low
$16.98
Div. Yield
0.0%

Valuation

P/B Ratio
0.33

Margins

Gross Margin 72.3%
Operating Margin 0.0%
Net Margin 9.9%
EBITDA Margin 17.7%

Growth & Returns

Revenue Growth (YoY)
34.0%
Earnings Growth (YoY)
935.1%
Earnings Growth (QoQ)
935.1%
Return on Equity
4.1%
Return on Assets
3.0%

Liquidity & Leverage

Current Ratio
3.86
Quick Ratio
2.65
Debt / Equity
0.06

About

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.

www.xvivogroup.com